Praxis Precision Medicines Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders such as epilepsy, movement disorders, and depression. Its approach uses genetic insights and neuroscience to target underlying brain-circuit dysfunctions. Praxis’s share performance is typically driven by trial readouts, regulatory progress, and investor sentiment toward innovative CNS drug development.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026


